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Visceral involvement associated with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)
and drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms
(DIHS/DRESS) is well documented. However, little is known about the long-term outcomes of severe
drug eruptions due to a lack of long-term follow-up. Long-term sequelae may arise in patients who
survive the acute complications of severe drug reactions. In SJS/TEN, extensive scarring that result from
the healing of mucocutaneous ulcerative lesions may interfere with organ function. Severe sequelae
include visual impairment and pulmonary obliterative disease that impair patients’ quality of life. In
DIHS/DRESS, recent observations suggest that fulminant type 1 diabetes mellitus (FT1D) and autoim-
mune diseases such as autoimmune thyroiditis and lupus erythematosus can occur after a disease-free
period of several months to years. Thus, DIHS/DRESS may lead to the development of autoimmune
diseases, which may be overlooked. Dermatologists need to be aware of the sequelae that may arise
following resolution of severe cutaneous adverse reactions and should be vigilant for manifestations of
autoimmune disease during follow-up.
Copyright  2013, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Severe cutaneous adverse eruptions include Stevens-Johnson syn-
drome/toxic epidermal necrolysis (SJS/TEN) and drug-induced hy-
persensitivity syndrome/drug reaction with eosinophilia and
systemic symptoms (DIHS/DRESS). Visceral involvement can occur
during the course of these diseases, including sepsis and pneu-
monitis in SJS/TEN, and hepatitis and renal failure in DIHS/DRESS.
However, the long-term sequelae after resolution of severe drug
eruptions is not well known, due to the lack of long-term follow-up
and the potential development of sequelae after a disease-free
period of several months to years. As there is limited information
on the long-term outcomes of severe drug eruptions,1e3 we present
a review on the long-term outcomes of SJS/TEN and DIHS/DRESS.
Sequelae in SJS/TEN
SJS/TEN are rare, potentially life-threatening conditions triggered
by drug administration and infections.4,5 SJS and TEN are nowy, Kyorin University School of
Japan. Tel.: þ81 422 47 5511;
iwanese Dermatological Associatiorecognized as variants of the same condition with differing sever-
ities. Although the pathomechanism of epidermal necrosis in SJS/
TEN remains unknown, various factors have been implicated,
including drug-speciﬁc T cells and/or monocytes/macrophages,6
regulatory T cell function,7,8 Fas/Fas ligand and perforin/granzyme
B,9 pro-inﬂammatory cytokines,10,11 and granulysin produced by
natural killer cells.12 The skin and mucous membrane are affected
in SJS/TEN, and mucosal involvement can be more severe than
cutaneous involvement. Healing of ulcerative mucosal lesions may
result in extensive scarring that interferes with organ function.
Ocular and dermatologic long-term sequelae may occur and affect
patients’ quality of life, emphasizing the need for long-term follow-
up of patients after resolution of SJS/TEN.
Ocular sequelae in SJS/TEN
Ocular sequelae in patients with SJS/TEN are well documented. The
involvement of the ocular surface is very common and can result in
long-term complications. In the acute disease, many patients
experience mild to severe ocular involvement,1 which include
conjunctivitis and epithelial sloughing in mild cases, and pseudo-
membranous and membranous conjunctivitis and corneal and/or
conjunctival epithelial defects with severe pain and photophobia in
severe cases.13 Inﬂammation of the ocular surface frequently persistn. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1 Sequelae in SJS/TEN.
Ocular lesion
Cornea: superﬁcial punctate keratinopathy, epithelial defect, loss of palisades of
Vogt, conjunctivalization, neovascularization, opaciﬁcation, keratinization
Conjunctiva: conjunctival hyperemia, symblepharon formation
Eyelid: trichiasis, mucocutaneous junction involvement, meibomian gland
involvement, lacrimal gland and duct involvements, punctal damage
Mucocutaneous lesion
Urogenital system: vaginal obstruction/vaginal stenosis, vulvovaginal adenosis/
endometriosis, urinary stream egress obstruction
Skin: pigmentary change, dry skin (xeroderma), appearance of melanocytic nevi
or ectopic sebaceous gland, nail deformity
Pulmonary lesion
Obliterative bronchitis/bronchiolitis
Esophageal lesion
Stricture formation
SJS/TEN ¼ Stevens-Johnson syndrome/toxic epidermal necrolysis.
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sequelae in chronic stage, at least 1 year from the onset of SJS/TEN.
Even minor involvement of the ocular surface in the acute disease
may lead to chronic ocular discomfort that requires long-term
therapy.
The ocular sequelae are broadly classiﬁed into three categories
depending on the involving area. Corneal sequelae include super-
ﬁcial punctate keratinopathy, epithelial defect, loss of the palisades
of Vogt, conjunctivalization, neovascularization, opaciﬁcation, and
keratinization. Conjunctival sequelae include conjunctival hyper-
emia and symblepharon formation. Eyelid sequelae include trichi-
asis, mucocutaneous junction involvement, meibomian gland
involvement, lacrimal gland and duct involvements, and punctal
damage (Figure 1).1 These lesions can cause prolonged ocular
discomfort and visual impairment, and may require long-term
therapy. Among ophthalmic problems, severe dry eye is the most
common long-term ocular sequela and is present in approximately
50% of patients with SJS/TEN. Trichiasis is also a common ocular
sequela. In particular, corneal involvement such as neo-
vascularization, opaciﬁcation, and keratinization correlates with
visual acuity (Table 1).
With respect to possible causes, Mycoplasma pneumoniae-
associated SJS induced more ocular involvement during the acute
stage than drug-induced SJS. Mycoplasma pneumoniae-associated
SJS seldom caused long-term ocular sequelae in children, while
adult patients remained at risk for long-term sequelae.14,15 Recent
genotype analyses revealed that multiplicative interactions of hu-
man leukocyte antigen (HLA)-A and Toll-like receptor 3 (TLR3)
genes might be required for the development of ocular complica-
tions in SJS/TEN.16
Mucocutaneous sequelae in SJS/TEN
Despite documented involvement of the genitals in female patients
with SJS/TEN, little information exists regarding long-term genital
complications. Genital involvement during SJS/TEN includes
erosive and ulcerative vaginitis, vulvar bullae, and vaginal syn-
echiae.17 Extensive scarring that affects genital function may occur
with the healing of mucosal ulcerations.
Vaginal or vulvar areas of necrosis may form adhesions. Very
few cases of symptomatic vaginal obstruction after SJS/TEN have
been documented. Pathologic changes in the vulvovaginal area
have been observed in women with SJS/TEN. Vulvovaginal adeno-
sis/endometriosisddeﬁned by the presence of metaplastic cervical
or endometrial glandular epithelium within the vaginal walldhas
been reported, causing dyspareunia and postcoital bleeding.17 TheFigure 1 Blepharosynechia after resolution of toxic epidermal necrolysis (TEN).cause remains unknown; it has been proposed that tubal or uterine
epithelium implant over the raw areas during SJS/TEN.18 The ma-
lignant potential of adenosis is unknown, but transformation to
adenosis with cellular atypia of the vagina has been reported.17 In a
pediatric case, extensive labial synechiae and hydrocolpos occurred
several years after an episode of SJS/TEN. Amenorrhea, cyclical
abdominal pain, or a hypogastric mass in girls after an episode of
SJS/TEN may indicate acquired vaginal obstruction. Thus, after a
diagnosis of SJS/TEN in girls, it is prudent to schedule a prepubertal
genital examination to avoid obstructed menstruation and future
sexual problems.18
Several strategies to prevent vulvovaginal sequelae have been
described. The application of intravaginal glucocorticoids, use of
vaginal molds, and menstrual suppression during SJS/TEN have
been proposed to reduce the formation of adhesions and limit
metaplastic changes in affected areas.17
Other mucosal sequelae resulting from an obstructed urinary
system include urinary retention and recurrent cystitis. Persistent
lingual ulcerations and recurrent oral aphthae can be observed
months after the resolution of SJS/TEN.19
Unlike mucous membranes, the skin usually heals within weeks
without scarring if wounds are treated adequately. The develop-
ment of hypertrophic scars in SJS/TEN has rarely been described in
the literature.20 Other cutaneous sequelae include dyspigmenta-
tion, nail deformity and ﬁngernail loss, and xeroderma. It is likely
that nail involvement is associated with ophthalmic involvement
(Figure 2).21 It is well known that Sjögren-like syndrome frequentlyFigure 2 Nail loss after resolution of toxic epidermal necrolysis (TEN).
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common complaints among survivors of SJS/TEN with involvement
of the eccrine duct, although the secretory gland is usually
normal.23
The sudden appearance of numerous melanocytic nevi
following severe bullous lesions in a patient with SJS had been
reported; it was speculated that the production of cytokines and
growth factors during epidermal regeneration may have led to the
proliferation of melanocytes.24 In a separate case, widespread
eruption of ectopic sebaceous glands occurred 4 months after an
episode of SJS.25 Similar to the aforementioned case, cytokines and
growth factors were thought to be responsible for the proliferation
of residual sebaceous gland cells.25
Pulmonary sequelae in SJS/TEN
The incidence of pulmonary involvement in SJS/TEN has not been
examined. Pulmonary involvement in SJS/TEN is divided into two
types: interstitial pneumonia during the course of SJS/TEN, and
obliterative bronchitis/bronchiolitis after the resolution of SJS/
TEN.26 According to one report, pulmonary sequelae tend to occur
in relatively young patients.27 A few cases of obliterative bronchitis/
bronchiolitis after SJS/TEN have been documented, as well as res-
piratory tract obstruction and bronchiectasis. The interval from the
onset of SJS/TEN to development of pulmonary sequela is unclear
because some reported cases show persistent respiratory symp-
toms from the onset of SJS/TEN.27
Obliterative bronchitis/bronchiolitis is diagnosed using imaging
and respiratory function tests, with ﬁndings of bronchiectasis on
high resolution computed tomography (CT) of the chest, occlusion
of the bronchus on bronchoscopy, and a severe obstructive pattern
in the ﬂowevolume curve. Although the pathomechanism remains
unknown, immunological pathways, infection, and remodeling of
the bronchial mucosa are implicated in the pulmonary sequelae of
SJS/TEN.
If patients suffer from recurrent respiratory symptoms after the
resolution of SJS/TEN, they should be closely monitored using res-
piratory function tests and CT. No effective treatment is available
for permanent obstructive pulmonary changes in obliterative
bronchitis/bronchiolitis. In severe cases, mechanical ventilation is
required, and living-donor lung transplantation may be necessary.
Patients with pulmonary sequela after resolution of SJS/TEN tend to
have a poor prognosis.
Esophageal sequelae in SJS/TEN
Long-term sequelae involving the gastrointestinal tract have rarely
been reported. Esophageal stricture as a consequence of SJS has
been reported in children but is rare in adults.28,29 Two patients had
foreign bodies lodged in esophageal strictures, occurring at 7
months after the episode of SJS in one case and at 18 months after
the episode of SJS in the other case. The delay in the onset of
dysphagia suggests that stricture formation may be subclinical. SJS/
TEN-related esophageal stricture is thought to occur because of
irritation caused by orally administrated medications, ingestion of
coarse food, or nasogastric feeding during SJS/TEN. Esophageal
strictures after SJS/TEN are easily dilated, suggesting that the con-
dition is caused by injury to the esophageal mucosa without
involvement of the muscularis.29
Sequelae in DIHS/DRESS
DIHS/DRESS is a severe adverse drug reaction caused by speciﬁc
drugs such as anticonvulsants and allopurinol, and is characterized
by visceral involvement and reactivation of human herpesviruses(HHV).30e32 Various internal organs can be affected during the
course of disease.33e39 Furthermore, the development of autoim-
mune diseases several months to years after clinical resolution of
DIHS/DRESS have been reported.2,3 Several autoimmune diseases
can develop sequentially in a single patient.40 The emergence of
autoimmune disease might be overlooked unless dermatologists
perform long-term follow-up of patients after their recovery from
DIHS/DRESS (Figure 3).41
Internal organ failure
Previous reports reveal that severe renal insufﬁciency increases the
risk of mortality, and mortality depends in part on the degree of
renal involvement rather than hepatic involvement.41 Renal insuf-
ﬁciency following after acute interstitial nephritis at the acute stage
of DIHS/DRESS could require a lifetime hemodialysis.2 It is more
likely to occur in elderly patients with pre-existing renal disease or
those receiving diuretic therapy. Because renal function declines
steadily with age, elderly patients are vulnerable to renal compli-
cations and sequelae.
Appearance of autoantibody after onset of DIHS/DRESS
Autoantibodies have been detected in patients with DIHS/DRESS
after resolution of the disease. According to an analysis of 34 cases
of DIHS/DRESS at our institution, autoantibodies such as anti-
nuclear antibody (ANA), anti-thyroperoxidase (TPO), and anti-
thyroglobulin antibodies were observed without any clinical
manifestations.3 The proportion of DIHS/DRESS patients with au-
toantibodies is higher than that seen in SJS/TEN patients.42 The
percentage of DIHS/DRESS patients with autoantibodies was higher
in the group that received supportive treatment alone than those
who received systemic corticosteroids.3 The autoantibody titers
ﬂuctuated but remained elevated during the observation period.
Our study showed that autoantibodies are present in some patients
after clinical resolution of DIHS/DRESS without causing clinically
overt diseases.
Autoimmune thyroid disease as a sequela in DIHS/DRESS
Thyroid disease is the most frequently detected sequela following
the resolution of DIHS/DRESS, with a cumulative incidence of 3.8%.
This incidence is more than 10-fold higher than the expected
incidence of this disease in the Chinese population.2 Endocrinologic
evaluation of patients with DIHS/DRESS revealed thyroid gland
abnormalities, such as increased free thyroxine (FT4), low thyroid-
stimulating hormone (TSH), and elevated TSH levels, and produc-
tion of autoantibodies, including anti-TSH receptor, anti-TPO, and
anti-thyroglobulin antibodies. As symptoms are not usually
observed, these abnormal ﬁndings may be missed if evaluation of
thyroid function and antibodies are not performed.
Graves’ disease may develop after the resolution of DIHS/DRESS.
Recently, it has been reported that the interval between discon-
tinuation of the causative drug and the onset of Graves’ disease is
approximately 2 months to 1 year. A recent case report described
the appearance of a diffuse large thyroid goiter followed by hy-
perthyroidism 2 months after the onset of sulfasalazine-induced
DIHS/DRESS.43 Thyrotoxicosis can be the initial presenting symp-
tom of thyroid disease.44 Two patients diagnosed with Graves’
disease with symptoms of hyperthyroidism and elevation in FT4
plus suppression of TSH have been documenteddone case had
symptoms 1 month after the onset of DIHS/DRESS while the other
had symptoms 9 months after the onset of DIHS/DRESS.2 Brown
et al described a patient with Graves’ disease conﬁrmed by thyroid
tests that developed 5 months after withdrawal of the causative
Figure 3 Autoimmune diseases developed after resolution of drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS). Six
out of the 37 patients with DIHS/DRESS developed autoimmune diseases in our institution. The period of follow-up was more than 6 months after the initiation of treatment. (-),
treated with systemic corticosteroid; (,), treated with supportive therapy alone; *, sclerodermoid graft-versus-host disease (GVHD)-like lesions.
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symptoms of hyperthyroidism, and tests for anti-TSH receptor
antibody and thyroid-stimulating immunoglobulin were negative
at that time. Autoimmune thyroiditis can develop following the
relapse of DIHS/DRESS.46
The emergence of Hashimoto’s disease, characterized by the
presence of anti-TPO antibody and anti-thyroglobulin antibodies,
has also been observed after the resolution of DIHS/DRESS. The
authors have encountered a patient with DIHS/DRESS who devel-
oped Hashimoto’s disease 3 years after resolution of the clinical
symptoms of DIHS/DRESS, characterized by elevated levels of anti-
TPO and anti-thyroglobulin antibodies.3 Alopecia has been noted in
patients with autoimmune thyroid disease.2,3,40 The presence of
HHV-6 in the thyroid was signiﬁcantly higher in Hashimoto’s
thyroiditis than in controls, highlighting a possible association
between HHV-6 reactivation and autoimmune thyroid disease.47,48
Type 1 diabetes mellitus as a sequela in DIHS/DRESS
Some cases of fulminant type 1 diabetes mellitus (FT1D) have been
associated with DIHS/DRESS.49e52 FT1D is a subtype of type 1
diabetes mellitus (T1D) characterized by an abrupt onset, absence
of islet-related autoantibodies, and nearly complete destruction of
pancreatic b-cells. The initial symptoms of T1D are vomiting and
dull epigastric pain; laboratory examinations reveal hyperglycemia,
hyperosmolarity and metabolic acidosis, and a relatively normal
glycosylated hemoglobin level; these features are compatible with
diabetic ketoacidosis. The onset of FT1D is characterized by
elevated levels of pancreatic exocrine enzymes such as lipase and
amylase, which is consistent with acute pancreatitis.
According to a nationwide survey in Japan, there were 15 cases
of FT1D associated with DIHS/DRESS between 1985 and 2010. The
mean age at onset of FT1D associated with DIHS/DRESS was 53.4
years; the interval between the onset of DIHS/DRESS to the devel-
opment of FT1D was 39.9 days (range, 13e199 days). The incidence
of FT1D in patients with DIHS/DRESS (0.54%) is much higher than
that in the general Japanese population (0.010%).53 The clinical
manifestations of FT1D associated with DIHS/DRESS are similar to
those not associated with DIHS/DRESS. It is possible that genetic
susceptibility contributes to the development of FT1D. Notably, the
incidence of HLA-B62 is signiﬁcantly increased in this type of dia-
betes mellitus in Japanese patients with DIHS/DRESS. Viral reac-
tivation may contribute to the development of FT1D in patients
with DIHS/DRESS, based on the observation that FT1D is associatedwith viral infections such as inﬂuenza B, HHV-6, herpes simplex
virus, and Coxsackie B3 virus.54,55 In this setting, the rapid and
severe damage to pancreatic b-cells may be caused by viral in-
fections, an immune response, or an interplay between viruses and
the immune response.56
By contrast, autoimmune T1D is rare in patients with DIHS/
DRESS. In autoimmune T1D, various autoantibodies including anti-
glutamic acid decarboxylase (GAD) and islet cell antibodies are
detected. The coexistence of autoimmune T1D and autoimmune
thyroiditis has been associated with DIHS/DRESS.45 In this case,
various autoantibodies including insulinoma antigen 2 (IA2), anti-
GAD, anti-TPO, anti-thyroglobulin, and anti-SSA antibodies and
ANA were detected over a period of several months. A case of T1D
following methimazole-induced hypersensitivity syndrome has
been reported,51 in which high glucose levels with a low serum C-
peptide were detected 5 months after the onset of DIHS/DRESS in a
patient with Graves’ disease. Interestingly, anti-GAD antibodies
were detected but at a relatively low level. A case of FT1D and
Hashimoto’s disease that developed concurrently after the onset of
DIHS/DRESS has been reported, characterized by the presence of
anti-thyroglobulin antibodies, ANA, and anti-SSA antibodies with
an absence of GAD and islet cell antibodies.57
The consequences of missing the diagnosis of T1D can be fatal. It
is essential to recognize the initial symptoms of T1D in patients
with DIHS/DRESS in order to initiate appropriate treatment.
Other sequelae in DIHS/DRESS
Besides autoimmune thyroiditis and T1D, other autoimmune
sequelaedheralded by autoimmune manifestations and/or pres-
ence of autoantibodiesdcan arise after resolution of DIHS/DRESS
following a symptom-free interval of several months to years.
These autoimmune diseases include sclerodermoid graft-versus-
host disease (GVHD)-like lesions,40 lupus erythematosus,58 auto-
immune hemolytic anemia (AIHA),2 and rheumatoid arthritis
(Table 2).
The authors have encountered three interesting cases of DIHS/
DRESS with autoimmune sequelae of sclerodermoid GVHD-like le-
sions and autoimmune thyroiditis, atypical SLE, and rheumatoid
arthritis, which appeared 3.5 years, 4 years, and 10 years after res-
olution of DIHS/DRESS, respectively. Theﬁrst patient had ahistoryof
zonisamide-induced DIHS/DRESS and presented with fatigue and
symptoms of thyroid dysfunction; diffuse alopecia on the scalp and
multiple ill-deﬁnedbrownish, induratedplaqueswithxerosis on the
Table 2 Autoimmune diseases as sequelae in DIHS/DRESS.
Alopecia
AIHA
Graves’ disease
Hashimoto’s disease
Lupus erythematosus
Rheumatoid arthritis
Sclerodermoid GVHD-like lesion
T1D (fulminant and autoimmune)
AIHA ¼ autoimmune hemolytic anemia; DIHS/DRESS ¼ drug-induced hypersensi-
tivity syndrome/drug reaction with eosinophilia and systemic symptoms;
GVHD ¼ graft-versus-host disease; T1D ¼ type 1 diabetes mellitus.
Y. Kano, T. Shiohara / Dermatologica Sinica 31 (2013) 211e216 215extremitieswereobservedonexamination.40 Interestingly, ANAwas
negative during the course of DIHS/DRESS, butwas detectable at the
time of presentation to our hospital.40 The second patient had a
history of carbamazepine-induced DIHS/DRESS with reactivation of
HHV-6 and EBV, and presented with a high-grade fever, general fa-
tigue, cervical lymphadenopathy, and erythematous lesions on his
face and ears.58 After resolution of DIHS/DRESS, he developed
prominent cervical lymphadenopathy. Histological ﬁndings of a
lymph node biopsy specimen were compatible with those of
Kikuchi-Fujimoto disease, and expression of EBV-encoded RNA
(EBER) was detected in the lymph node by in situ hybridization, but
not in the blood. Clinical manifestations of SLE including fever,
general fatigue, discoid lesions, leucopenia, and proteinuria
appeared 2 weeks after the onset of Kikuchi-Fujimoto disease. The
third patient had a history of carbamazepine-induced DIHS/DRESS
with the appearance of autoantibodies such as ANA, anti-TPO, and
anti-thyroglobulin antibodies after the resolution of DIHS/DRESS.
The autoantibody levelsﬂuctuatedwithout overt clinical symptoms.
Ten years after the onset of DIHS/DRESS, the patient developed
rheumatoid arthritis with characteristic joint deformities of the
hands. It was noted that the second and third cases of DIHS/DRESS
hadbeen treatedwith supportive therapyalone. Chenet al described
a case of AIHA and suspected SLE after the resolution of dapsone-
induced DIHS/DRESS.2 In that case, the patient had a high lactate
dehydrogenase level, elevated percentage of reticulocytes,
decreased haptoglobin concentration, and a positive Coombs test.
Pathomechanism of autoimmune disease in DIHS/DRESS
The pathomechanism underlying the emergence of autoimmune
disease in DIHS/DRESS is poorly understood. A genetic suscepti-
bility may contribute to their development.53 Based on long-term
follow-up of patients with DIHS/DRESS, several observations
regarding the development of autoimmune sequelae were noted:
young patients2 and those treated with non-corticosteroid therapy
were more susceptible,3 and that herpesvirus reactivationdin
particular, Epstein-Barr virus reactivationdis implicated in its
development.3,56
From an immunological perspective, our previous study showed
that the number of fully functional CD4þCD25þFoxP3þ regulatory T
(Treg) cells is markedly increased during the course of DIHS/DRESS
compared with other drug reactions, which contributed to viral
reactivation. These FoxP3þ T cells lost their ability to inhibit the
cytokine production and proliferation of effector T cells, which
coincided with their contraction upon clinical resolution of DIHS/
DRESS. The functional defect of Treg cells might be responsible for
the development of autoimmune disease.8,56,59
Conclusion
In summary, the development of long-term sequelae after resolu-
tion of severe cutaneous adverse drug reactions may be overlookedbecause of an asymptomatic interval after resolution of the acute
disease. The emergence of sequelae should be closely monitored
following the resolution of SJS/TEN and DIHS/DRESS, especially
autoimmune disease in DIHS/DRESS. The reactivation of herpesvi-
ruses and development of autoimmune disease in DIHS/DRESSmay
indicate a possible link between viral infections and autoimmune
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